TreatSMA

Trustee Joseph Irwin looks back at 30 years of changes in EU legislation in drug development for rare diseases in his latest paper

TreatSMA trustee Joseph Irwin looks back at 30 years of changes in EU legislation in drug development for rare diseases in his latest paper.

In the latest volume of Regulatory Rapporteur, TreatSMA trustee Joseph Irwin has publish a paper titled  ‘A look back at 30 years of changes in EU legislation in drug development for rare diseases’. In this paper Joseph reflects on some milestones of the evolving EU framework for the development and evaluation of medicines for rare diseases.

TreatSMA are incredibly thankful for, and proud of, the research and contributions Joseph has made to research for rare diseases in the last 30 years. For his full paper, please see the link below.

A look back at 30 years of changes in EU legislation in drug development for rare diseases

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more